<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00486421</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000529883</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>MC0481</secondary_id>
    <secondary_id>2071-04</secondary_id>
    <secondary_id>U2985s</secondary_id>
    <nct_id>NCT00486421</nct_id>
  </id_info>
  <brief_title>Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura</brief_title>
  <official_title>A Pilot Study of Rituximab in Combination With Corticosteroids for the Initial Treatment of Immune Thrombocytopenic Purpura</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Rituximab and prednisone may increase the number of platelets in patients with&#xD;
      immune thrombocytopenic purpura.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects and how well giving rituximab&#xD;
      together with prednisone works as first-line therapy in treating patients with immune&#xD;
      thrombocytopenic purpura.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the efficacy of rituximab, when administered with standard prednisone&#xD;
           treatment, in maintaining a platelet count ≥ 50,000/mm³ at 6 months without further&#xD;
           therapies (e.g., splenectomy or other salvage therapies) in patients with immune&#xD;
           thrombocytopenic purpura.&#xD;
&#xD;
        -  Determine the safety of this regimen in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the time to platelet recovery in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the duration of platelet recovery in patients treated with this regimen.&#xD;
&#xD;
        -  Assess efficacy of this regimen in preventing spontaneous bleeding events in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
      Patients receive rituximab IV on days 1, 8, 15, and 22 and oral prednisone once daily on days&#xD;
      1-14 followed by a taper to day 56. Treatment is administered in the absence of disease&#xD;
      relapse or unacceptable toxicity.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically for up to 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failure-free survival at 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to platelet recovery</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of platelet recovery</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of treatment on prevention of spontaneous bleeding events</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Nonneoplastic Condition</condition>
  <arm_group>
    <arm_group_label>PRED &amp; RITUX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375mg/m2 IV weekly times 4 (days 1, 8, 15, 22)</description>
    <arm_group_label>PRED &amp; RITUX</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>1mg/kg/d PO, taper to off by 8 weeks</description>
    <arm_group_label>PRED &amp; RITUX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of immune thrombocytopenic purpura (ITP)&#xD;
&#xD;
               -  Diagnosis must be made according to American Society of Hematology diagnostic&#xD;
                  guidelines by a member of Mayo Rochester's Division of Hematology/Oncology within&#xD;
                  the past year&#xD;
&#xD;
               -  ITP must be confirmed by bone marrow aspiration and biopsy in all patients ≥ 60&#xD;
                  years of age*&#xD;
&#xD;
                    -  Bone marrow studies performed outside Mayo must be reviewed by a Mayo&#xD;
                       hematopathologist to confirm diagnosis and exclude evidence of other&#xD;
                       hematologic disorders NOTE: *Bone marrow evaluation is discretionary for all&#xD;
                       other patients&#xD;
&#xD;
          -  Requires treatment, as defined by 1 of the following parameters:&#xD;
&#xD;
               -  Platelet count ≤ 30,000/mm³&#xD;
&#xD;
               -  Platelet count ≤ 50,000/mm³ with episodic bleeding (i.e., spontaneous or with&#xD;
                  minimal trauma) requiring treatment&#xD;
&#xD;
          -  No concurrent diagnosis of a condition known to cause secondary immune (or nonimmune)&#xD;
             thrombocytopenia, including, but not limited to, any of the following:&#xD;
&#xD;
               -  Rheumatological conditions, such as lupus, rheumatoid arthritis, scleroderma, or&#xD;
                  mixed connective tissue disorder&#xD;
&#xD;
                    -  Patients with positive serologies and no concurrent, clinically evident&#xD;
                       condition are eligible&#xD;
&#xD;
               -  HIV positive or AIDS&#xD;
&#xD;
               -  Non-Hodgkin's lymphoma, Hodgkin's lymphoma, chronic lymphocytic lymphoma,&#xD;
                  multiple myeloma, or other malignant hematological conditions&#xD;
&#xD;
               -  Clinically evident antiphospholipid antibody syndrome* or heparin-induced&#xD;
                  thrombocytopenia&#xD;
&#xD;
               -  Clinically overt liver disease, hepatitis B surface antigen positive, hepatitis C&#xD;
                  serology positive, or evidence of a microangiopathic hemolytic anemia, such as&#xD;
                  disseminated intravascular coagulation, hemolytic-uremic syndrome, thrombotic&#xD;
                  thrombocytopenic purpura, or preeclampsia NOTE: *Positive laboratory tests&#xD;
                  without the defined clinical criteria for a diagnosis of antiphospholipid&#xD;
                  antibody syndrome is allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Creatinine ≤ 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Direct bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  AST ≤ 2.5 times ULN&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  WBC ≥ 3,000/mm³&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No hypersensitivity to murine or chimeric proteins&#xD;
&#xD;
          -  No other disease, metabolic dysfunction, physical examination finding, or clinical&#xD;
             laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use of an investigational drug or that may affect the&#xD;
             interpretation of the results or render the patient at high risk for treatment&#xD;
             complications&#xD;
&#xD;
          -  Able to take a proton-pump inhibitor while on corticosteroids&#xD;
&#xD;
          -  No unresolved or incompletely treated infection within the past 14 days&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior corticosteroid therapy since the diagnosis of ITP&#xD;
&#xD;
               -  Corticosteroid therapy is allowed for up to 14 days prior to study entry, once&#xD;
                  the baseline CBC has been established&#xD;
&#xD;
          -  No prior rituximab&#xD;
&#xD;
          -  No other concurrent therapy for ITP, including androgens, IV immunoglobulins, RH_o (D)&#xD;
             immune globulin, cyclosporine, or azathioprine sodium&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruben A. Mesa, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>June 13, 2007</study_first_submitted>
  <study_first_submitted_qc>June 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2007</study_first_posted>
  <last_update_submitted>October 15, 2014</last_update_submitted>
  <last_update_submitted_qc>October 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>idiopathic thrombocytopenic purpura</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

